Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies.
Saved in:
| Title: | Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies. |
|---|---|
| Authors: | Dreyzin A; Center for Cellular Engineering, National Institutes of Health Clinical Center, Bethesda, Maryland, USA; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Kramer AM; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, California, USA; Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Stanford, California, USA., Yates B; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Wang HW; Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland, USA., Sahaf B; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, California, USA; Stanford University School of Medicine, Cancer Correlative Science Unit, Stanford Cancer Institute, Stanford, California, USA., Yuan C; Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland, USA., Klysz D; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, California, USA; Laboratory for Cell and Gene Medicine, Stanford University, Stanford, California, USA., Tunuguntla R; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, California, USA; Laboratory for Cell and Gene Medicine, Stanford University, Stanford, California, USA., Ehlinger Z; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, California, USA; Stanford University School of Medicine, Cancer Correlative Science Unit, Stanford Cancer Institute, Stanford, California, USA., Reitberg S; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, California, USA., Adebola S; Immunodynamics Section, Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA., Su A; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Ebina-Shibuya R; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA; Department of Medical Science and Innovation, SiRIUS Institute of Medical Research, Tohoku University, Sendai, Japan and Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan., Jia D; Immunodynamics Section, Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA., Achar S; Immunodynamics Section, Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA., Patil S; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, California, USA; Stanford University School of Medicine, Cancer Correlative Science Unit, Stanford Cancer Institute, Stanford, California, USA., Martin K; Center for Cellular Engineering, National Institutes of Health Clinical Center, Bethesda, Maryland, USA., Jeyakumar N; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, California, USA; Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Stanford, California, USA., Davis KL; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, California, USA; Department of Pediatrics, Division of Pediatric Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Stanford University, Stanford, California, USA., Fry T; Department of Pediatrics and Immunology, Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora, Aurora, Colorado, USA., Mackall CL; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, California, USA; Department of Pediatrics, Division of Pediatric Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Stanford University, Stanford, California, USA., Taylor N; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Altan-Bonnet G; Immunodynamics Section, Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA., Highfill S; Center for Cellular Engineering, National Institutes of Health Clinical Center, Bethesda, Maryland, USA., Feldman S; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, California, USA; Laboratory for Cell and Gene Medicine, Stanford University, Stanford, California, USA., Stroncek DF; Center for Cellular Engineering, National Institutes of Health Clinical Center, Bethesda, Maryland, USA., Chien C; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Schultz LM; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, California, USA; Department of Pediatrics, Division of Pediatric Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Stanford University, Stanford, California, USA., Frank MJ; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, California, USA; Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Stanford, California, USA., Muffly LS; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, California, USA; Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Stanford, California, USA., Shalabi H; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Ramakrishna S; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, California, USA; Department of Pediatrics, Division of Pediatric Hematology, Oncology, Stem Cell Transplant and Regenerative Medicine, Stanford University, Stanford, California, USA. Electronic address: ramakrs@stanford.edu., Shah NN; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. Electronic address: nirali.shah@nih.gov. |
| Source: | Cytotherapy [Cytotherapy] 2026 Mar; Vol. 28 (3), pp. 101990. Date of Electronic Publication: 2025 Oct 02. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 100895309 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-2566 (Electronic) Linking ISSN: 14653249 NLM ISO Abbreviation: Cytotherapy Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
